Search Results | Blood | American Society of Hematology

1-20 of 60

2 3

Sort by

Sort Order Select

Journal Articles

Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL

Bernard D Maybury, Findlay Bewicke-Copley, Peter Johnson, Jude Fitzgibbon, Dinis Pedro Calado

Blood (2021) 138 (Supplement 1): 2401.

DOI: https://doi.org/10.1182/blood-2021-152318

Published: 2021

Journal Articles

The Paradoxical Efficacy of KDM6 Inhibition in Germinal Centre B-Cell Lymphomas

Karina Close, Hannah Armes, Emil Kumar, Findlay Bewicke-Copley, Adam Cribbs, James Dunford, Martin Philpott, Udo Oppermann, James Heward, Jude Fitzgibbon

Blood (2021) 138 (Supplement 1): 3289.

DOI: https://doi.org/10.1182/blood-2021-146392

Published: 2021

Journal Articles

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Verena Passerini, Vindi Jurinovic, Christopher R Bolen, Andrea Knapp, Alessia Bottos, Julia Richter, Jude Fitzgibbon, Wolfram Klapper, Andrew Davies, Robert Marcus, Michael von Bergwelt, Tina Nielsen, Martin H. Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert

Blood (2021) 138 (Supplement 1): 39.

DOI: https://doi.org/10.1182/blood-2021-147751

Published: 2021

Journal Articles

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Blood (2021) 138 (5): 370–381.

DOI: https://doi.org/10.1182/blood.2020008743

Published: 2021

Includes: Supplemental data

Journal Articles

Germline ETV6 variants: not ALL created equally

Ana Rio-Machin, Jude Fitzgibbon

Blood (2021) 137 (3): 288–289.

DOI: https://doi.org/10.1182/blood.2020008190

Published: 2021

Journal Articles

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 39–40.

DOI: https://doi.org/10.1182/blood-2020-141345

Published: 2020

Journal Articles

Systematic Evaluation of Somatic Cis -Regulatory Mutations in Follicular Lymphoma

Firat Uyulur, MSc, Findlay Bewicke-Copley, PhD MSc, BSc, Chinedu Anthony Anene, PhD, Matthias Schlesner, PhD, Icgc MMML-Seq Project, Reiner Siebert, Prof. Dr. MD, Jessica Okosun, MD PhD, Jude Fitzgibbon, PhD, Jun Wang, PhD

Blood (2020) 136 (Supplement 1): 26–27.

DOI: https://doi.org/10.1182/blood-2020-142623

Published: 2020

Journal Articles

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Blood (2019) 134 (Supplement_1): 2769.

DOI: https://doi.org/10.1182/blood-2019-124352

Published: 2019

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

DOI: https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Anna L. Brown, PhD BSc, Mark Armstrong, MSc, David Lawrence, Paul Wang, Peer Arts, PhD, Nicolas Duployez, PharmD, PhD, Jane Churpek, MD, Kiran Tawana, MD, Erin Degelman, MSc, BSc, Georges Natsoulis, PhD, Monica L. Guzman, PhD, Mrinal M. Patnaik, MD MBBS, Akiko Shimamura, MD PhD, Alan B. Cantor, MD PhD, Tim Ripperger, MD PhD, Brigitte Schlegelberger, MD PhD, Doris Steinemann, PhD, Courtney D. DiNardo, MD MSc, Cristina Mecucci, MD PhD, Elvira DRP Velloso, MD PhD, Fabio PS Santos, MD, Marcela CA Silva, Uma Borate, MD, Shannon K. McWeeney, PhD, Grzegorz Nalepa, MD PhD, Susanne Ragg, MD PhD, Erika Mijin Kwon, PhD, Anupriya Agarwal, PhD, Stephen Langabeer, PhD, Jeffery M. Klco, MD PhD, Jun J. Yang, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Sally Mapp, MD PhD, Helen Mar Fan, MD, Lesley Rawlings, PhD, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Andrew H Wei, MBBS,PhD, Inderjeet Dokal, MD, Tom Vulliamy, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MD FRACP, FRCPA, Susan Branford, PhD, Elli Papaemmanuil, PhD, Jean Soulier, MDPhD, Stefan Fröhling, MD, Alwin Kramer, MD, Guy Sauvageau, MD PhD, Neil Morgan, Carolyn Owen, Csaba Bödör, PhD, Jude Fitzgibbon, Hugh Y. Rienhoff, Jr., MD, Mineo Kurokawa, MD PhD, Lucy Godley, MD PhD, Claude Preudhomme, Paul P Liu, MD PhD, Nicola Poplawski, MD, Christopher N. Hahn, PhD, Hamish S. Scott, PhD

Blood (2018) 132 (Supplement 1): 5241.

DOI: https://doi.org/10.1182/blood-2018-99-118017

Published: 2018

Journal Articles

Homozygous OB-fold variants in telomere protein TPP1 are associated with dyskeratosis congenita–like phenotypes

Hemanth Tummala, Laura C. Collopy, Amanda J. Walne, Alicia Ellison, Shirleny Cardoso, Tekin Aksu, Nese Yarali, Deniz Aslan, Rüştü Fikret Akata, Juliana Teo, Zhou Songyang, Nikolas Pontikos, Jude Fitzgibbon, Kazunori Tomita, Tom Vulliamy, Inderjeet Dokal

Blood (2018) 132 (12): 1349–1353.

DOI: https://doi.org/10.1182/blood-2018-03-837799

Published: 2018

Includes: Supplemental data

Journal Articles

Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma

Blood (2017) 130 (Supplement 1): 2730.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2730.2730

Published: 2017

Journal Articles

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Blood (2017) 130 (Supplement 1): 2734.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2734.2734

Published: 2017

Journal Articles

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Larry Mansouri, Daniel Noerenberg, Emma Young, Elena Mylonas, Maysaa Abdulla, Mareike Frick, Fazila Asmar, Viktor Ljungström, Markus Schneider, Kenichi Yoshida, Aron Skaftason, Tatjana Pandzic, Blanca Gonzalez, Anna Tasidou, Nils Waldhueter, Alfredo Rivas-Delgado, Maria Angelopoulou, Marita Ziepert, Christopher Maximilian Arends, Lucile Couronné, Dido Lenze, Claudia D. Baldus, Christian Bastard, Jessica Okosun, Jude Fitzgibbon, Bernd Dörken, Hans G. Drexler, Damien Roos-Weil, Clemens A. Schmitt, Helga D. Munch-Petersen, Thorsten Zenz, Martin-Leo Hansmann, Jonathan C. Strefford, Gunilla Enblad, Olivier A. Bernard, Elisabeth Ralfkiaer, Martin Erlanson, Penelope Korkolopoulou, Magnus Hultdin, Theodora Papadaki, Kirsten Grønbæk, Armando Lopez-Guillermo, Seishi Ogawa, Ralf Küppers, Kostas Stamatopoulos, Niki Stavroyianni, George Kanellis, Andreas Rosenwald, Elias Campo, Rose-Marie Amini, German Ott, Theodoros P. Vassilakopoulos, Michael Hummel, Richard Rosenquist, Frederik Damm

Blood (2016) 128 (23): 2666–2670.

DOI: https://doi.org/10.1182/blood-2016-03-704528

Published: 2016

Includes: Supplemental data

Journal Articles

Genomic Discovery, Prognosis, and Target Therapy Development

Jude Fitzgibbon, PhD

Blood (2016) 128 (22): SCI-6.

DOI: https://doi.org/10.1182/blood.V128.22.SCI-6.SCI-6

Published: 2016

Journal Articles

Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets

David J Britton, PhD, Edmund Wilkes, BSc, PhD, Pedro Casado, PhD, Vinothini Rajeeve, PhD, Jude Fitzgibbon, John Gribben, Pedro R Cutillas, BSc, PhD

Blood (2016) 128 (22): 5265.

DOI: https://doi.org/10.1182/blood.V128.22.5265.5265

Published: 2016

Journal Articles

ΝFΚΒΙΕ Deletions : A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma

Daniel Noerenberg*, Larry Mansouri*, Emma Young, Frick Mareike, Maysaa Abdulla, Fazila Asmar, Blanca Gonzalez-Farre, Tasidou Anna, Nils Waldhueter, Viktor Ljungström, Alfredo Rivas, Maria K. Angelopoulou, Marita Ziepert, Christopher M. Arends, Lucile Couronne, Dido Lenze, Claudia D. Baldus, MD, Christian Bastard, Jessica Okosun, Jude Fitzgibbon, Bernd Dörken, Hans G. Drexler, Damien Roos-Weil, Clemens A. Schmitt, Helga Duverger Munch-Petersen, Thorsten Zenz, Jonathan C. Strefford, Gunilla Enblad, Olivier A. Bernard, Elisabeth Ralfkiaer, Penelope Korkolopoulou, Magnus Hultdin, Theodora Papadaki, Kirsten Grønbæk, Armando Lopez-Guillermo, Kostas Stamatopoulos, MD PhD, Niki Stavroyianni, George Kanellis, Andreas Rosenwald, MD, Elias Campo, Rose-Marie Amini, German Ott, Theodoros Vassilakopoulos, Michael Hummel, Frederik Damm**, Richard Rosenquist**

Blood (2016) 128 (22): 609.

DOI: https://doi.org/10.1182/blood.V128.22.609.609

Published: 2016

Journal Articles

Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors

Brian J.P Huntly, MD PhD, Sarah Jayne Horton, BSc, PhD, George Giotopoulos, Haiyang Yun, MD PhD, Shabana Vohra, BSc, PhD, Olivia Sheppard, Bsc, PhD, Rachael Bashford-Rogers, PhD, Mamunur Rashid, PhD, Daniel Sasca, MD, Faisal Basheer, MBBChir, MA, Paolo Gallipoli, MD PhD, Jessica Okosun, Daniel James Hodson, MD PhD, Jude Fitzgibbon, Ming Du, David Adams

Blood (2016) 128 (22): 460.

DOI: https://doi.org/10.1182/blood.V128.22.460.460

Published: 2016

Journal Articles

Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors

Pedro Casado, PhD, Edmund Wilkes, PhD, Marym M Hadi, Vinothini Rajeeve, PhD, Farideh Miraki-Moud, PhD, Rebecca Pike, PhD, Ana Del Rio-Machin, PhD, Sameena Iqbal, Jude Fitzgibbon, PhD, John Gribben, Pedro R Cutillas, BSc, PhD

Blood (2016) 128 (22): 840.

DOI: https://doi.org/10.1182/blood.V128.22.840.840

Published: 2016

Journal Articles

HDAC Inhibitors As Novel Targeted Therapies for NUP98-HOXA9 AML Patients

Ana Rio-Machin, BSc, MSc, PhD, Gonzalo Gomez-Lopez, BSc, PhD, Alba Maiques-Diaz, BSc, MSc, PhD, Sara Alvarez, MD PhD, Maria Jose Calasanz, BSc, PhD, Jude Fitzgibbon, Juan C Cigudosa, BSc, PhD

Blood (2016) 128 (22): 2685.

DOI: https://doi.org/10.1182/blood.V128.22.2685.2685

Published: 2016

2 3

NARROW

Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL

The Paradoxical Efficacy of KDM6 Inhibition in Germinal Centre B-Cell Lymphomas

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

Germline ETV6 variants: not ALL created equally

Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

Systematic Evaluation of Somatic Cis -Regulatory Mutations in Follicular Lymphoma

Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Homozygous OB-fold variants in telomere protein TPP1 are associated with dyskeratosis congenita–like phenotypes

Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma

Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

Genomic Discovery, Prognosis, and Target Therapy Development

Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets

ΝFΚΒΙΕ Deletions : A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma

Early Loss of CREBBP Confers Malignant Stem Cell Properties on Lymphoid Progenitors

Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors

HDAC Inhibitors As Novel Targeted Therapies for NUP98-HOXA9 AML Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only